Johannes Schmöllerl

8PUBLICATIONS
72CO-AUTHORS
Haematological tumoursPredictive and prognostic markersMolecular targetsCancer cell biologyNeurology and neuromuscular diseases
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Nov 26, 2025
Lymphotoxin alpha eradicates acute myeloid leukemia and simultaneously promotes healthy hematopoiesis in mice.

Ulrike Höckendorf, Sayantanee Dutta, Arnold Kloos

|May 19, 2025
Transcriptional and epigenetic rewiring by the NUP98::KDM5A fusion oncoprotein directly activates CDK12.

Selina Troester, Thomas Eder, Nadja Wukowits

|Sep 22, 2023
The NCOR-HDAC3 co-repressive complex modulates the leukemogenic potential of the transcription factor ERG.

Eitan Kugler, Shreyas Madiwale, Darren Yong

|Sep 19, 2023
ABCC1 and glutathione metabolism limit the efficacy of BCL-2 inhibitors in acute myeloid leukemia.

Jessica Ebner, Johannes Schmoellerl, Martin Piontek

|Jan 11, 2023
SBNO2 is a critical mediator of STAT3-driven hematological malignancies.

Tania Brandstoetter, Johannes Schmoellerl, Reinhard Grausenburger

|Sep 12, 2022
EVI1 drives leukemogenesis through aberrant ERG activation.

Johannes Schmoellerl, Inês A M Barbosa, Martina Minnich

Pageof 2